Any current/future new fundraising through debt or equity?

There is no mention of any current plans for new fundraising through debt or equity. The company remains debt-free as of the latest report (FY26), with a cash balance of INR 990 crores. Management is focused on deploying available cash for potential acquisitions rather than raising new funds. Discussions are ongoing for two acquisition targets, with due diligence in progress on one, indicating a preference for using existing cash resources. Management emphasizes conservative financial management, including maintaining R&D spending at around 3%. No explicit guidance was provided about future fu

Any current/future capex/capital investment/strategic investment?

Capex during FY26 was INR131 crores, primarily for the new facility and ongoing maintenance. Major capex cycle now complete, with free cash flow generation improving steadily. Planning additional capex within the Teva facility to launch different dosage forms not currently available. Management actively exploring acquisition targets for strategic growth; ongoing due diligence on two potential targets. 2027 expected to see some M&A activity funded by INR990 crores cash balance. Focus on value-accretive acquisitions across different geographies, conservatively valued to ensure return o

Future growth expectations in sales/revenue/volumes?

Marksans Pharma targets to double revenue in the next 3 to 5 years, aiming for INR4,000 crores by FY28. Growth drivers include strong expansion in the U.S. market, Europe (especially U.K. and Germany), and Australia/New Zealand. Australia is expected to reach $100 million in revenue within 3 years, with ongoing new product launches. Europe and Canada markets are being developed organically, with product filings underway and revenue expected to start trickling in by late FY27. Capacity utilization currently about 50-55%, with spare capacity to support growth before expansion. The company plans

Future growth expectations in earnings/operating earnings/profits/EPS?

Marksans Pharma aims to double its revenue in the next 3 to 5 years, targeting INR4,000 crores by FY28. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin guidance remains stable at around 20-22%, despite raw material inflation pressures. Profit after tax and Earnings Per Share (EPS) showed strong growth in FY26 with a 64.3% increase in PAT and EPS reaching INR9.2. The company expects continued growth driven by diversification into new geographies like Europe (Germany, Canada), strong U.S. market growth, and expanding presence in Australia and U.K. Mark Saldanha no

IN US

Sale is live|00:00:00left today

Marksans Pharma LtdQ1 FY26Pharmaceuticals & Biotechnology

Marksans Pharma Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹265P/E: 23.2Market Cap: ₹8.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Marksans Pharma targets to double revenue in the next 3 to 5 years, aiming for INR4,000 crores by FY28.
→Growth drivers include strong expansion in the U.S. market, Europe (especially U.K. and Germany), and Australia/New Zealand.
→Australia is expected to reach $100 million in revenue within 3 years, with ongoing new product launches.
→Europe and Canada markets are being developed organically, with product filings underway and revenue expected to start trickling in by late FY27.
→Capacity utilization currently about 50-55%, with spare capacity to support growth before expansion.
→The company plans to file over 200 products in the U.K. over the next 4 years, expanding the product pipeline continuously.
→Revenue growth guidance is conservatively 15-20% annually in near term.
→Growth across all geographies is expected, with U.S. as the primary driver, but Europe and Australia gaining importance.

Margin guidance

Category 3

→Marksans Pharma aims to double its revenue in the next 3 to 5 years, targeting INR4,000 crores by FY28.
→Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin guidance remains stable at around 20-22%, despite raw material inflation pressures.
→Profit after tax and Earnings Per Share (EPS) showed strong growth in FY26 with a 64.3% increase in PAT and EPS reaching INR9.2.
→The company expects continued growth driven by diversification into new geographies like Europe (Germany, Canada), strong U.S. market growth, and expanding presence in Australia and U.K.
→Mark Saldanha noted pricing pressures in the U.S. but relatively better margins in Europe and U.K.
→R&D spend will be maintained at about 3% of revenues to support product pipeline and launches, bolstering future earnings growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current plans for new fundraising through debt or equity.
→The company remains debt-free as of the latest report (FY26), with a cash balance of INR 990 crores.
→Management is focused on deploying available cash for potential acquisitions rather than raising new funds.
→Discussions are ongoing for two acquisition targets, with due diligence in progress on one, indicating a preference for using existing cash resources.
→Management emphasizes conservative financial management, including maintaining R&D spending at around 3%.
→No explicit guidance was provided about future fundraising; the focus is on organic growth and acquisitions funded from existing cash and cash flow.

Order book

The transcript from Marksans Pharma Limited's Q4 FY26 investor/analyst meet does not explicitly mention the current or expected order book or pending orders. However, some related points to their business outlook and growth plans include: - Strong growth in multiple geographies like U.S., Europe (including U.K.), Australia, and Canada with an expanding product pipeline. - A healthy and growing product pipeline, with about 50+ new products expected for filing in the U.S. in FY27 and larger pipelines in other geographies. - Canada products are under filing with expected approvals in late FY26. - Australia/New Zealand business targeting $100 million revenue milestone within 3 years. - Focus on acquiring and integrating new assets in key geographies to diversify platforms. - Continuing to build inventory to mitigate supply chain uncertainties and geopolitical risks. - Management confident of doubling revenue in the next 3 to 5 years. No specific order book or pending order figures were disclosed.

Capex plans

Yes

→Capex during FY26 was INR131 crores, primarily for the new facility and ongoing maintenance.
→Major capex cycle now complete, with free cash flow generation improving steadily.
→Planning additional capex within the Teva facility to launch different dosage forms not currently available.
→Management actively exploring acquisition targets for strategic growth; ongoing due diligence on two potential targets.
→2027 expected to see some M&A activity funded by INR990 crores cash balance.
→Focus on value-accretive acquisitions across different geographies, conservatively valued to ensure return on investment.
→No current plans for buying remaining stake in Australia/New Zealand entity as partners are effectively growing the business.
→Capacity expansions planned but currently have spare capacity; land bank expansion or new plants under consideration for future scale-up.

How does Marksans Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Marksans Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Marksans Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio